Jamjoom Pharma Strikes Strategic Deal with Bio-Thera for securing Cosentyx® Biosimilar in MENA
Under the agreement, Jamjoom Pharma will obtain the exclusive rights to commercialize BAT2306 - a proposed biosimilar to Novartis’ Cosentyx® (secukinumab) - across the Middle East and North Africa (MENA) region. Jamjoom Pharma will manage regulatory submissions, market access, and commercialization in MENA, while Bio-Thera will oversee product development and global manufacturing from its state-of-the-art facilities in Guangzhou, China.
“This collaboration is a strategic milestone for Jamjoom Pharma and a testament to our mission of broadening access to advanced biologics in the MENA region,” said Tarek Hosni, Chief Executive Officer of Jamjoom Pharma. “By joining forces with Bio-Thera, we are combining world-class biosimilar development with Jamjoom’s deep regional expertise, strong commercial capabilities, and commitment to delivering high-quality, affordable therapies. This agreement strengthens our leadership in the biopharmaceutical sector and reinforces our role as a trusted partner in improving patient outcomes.”
“Bio-Thera is committed to bringing affordable medicines to patients in need around the world, “ said Bert Thomas, Senior Vice President of Business Development. “Partnering with JamJoom Pharma to bring BAT2306 to patients in the MENA region is a demonstration of that commitment. We are proud to partner with Jamjoom Pharma and look forward to a successful collaboration.
For More Information
Influence communications
email us here
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
